Jubilant Life Sciences receives USFDA approval for Telmisartan

Jubilant Life Sciences has received USFDA approval for Telmisartan Tablets, used for the treatment of hypertension, in the U.S. market. The final approval is for marketing Telmisartan Tablets, USP 20,40 and 80mg which is the generic version of Micardis Tablets of Boehringer Ingelheim Pharmaceuticals Inc. As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the U.S., of which 44 have been approved and 104 filings in Europe.

Company Profile : Jubilant Life Sciences Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.